| Metric | Value | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue | 2.6K Cr | 21.6% | 36.4% |
| Total Income | 2.6K Cr | 21.8% | 35.4% |
| Expenditure | 2.1K Cr | 16.3% | 20.7% |
| PBT | 467.63 Cr | 55.2% | 202.2% |
| Net Profit | 345.01 Cr | 56.9% | 207.4% |
| OPM | 20.96% | 3.23pp | 10.93pp |
| NPM | 13.31% | 2.98pp | 7.45pp |
| EPS | 25.30 | 57.0% | 207.4% |
Detailed report is being prepared.
Margin Momentum in Motion — What Q1 FY27 Will Signal
Deepak Nitrite enters Q1 FY27 with a margin recovery in train and capex ambitious for specialty chemicals. The quarter will test whether Q4's 18% EBITDA margin holds, and whether the street's 21–36% upside thesis rests on execution.
What to Expect
~₹1,650 Cr
Q1 typically lower than Q4; prior analyst range ₹1,566–1,763 Cr. Last year Q1 FY26 was ₹1,809 Cr.
~17–19%
Q4 FY26 delivered 18%; FY26 full-year average was 13%. Watch for sustainability of the recovery.
~₹280–315 Cr
Indexed off expected revenue and margin. FY26 full-year EBITDA was ₹1,041 Cr (~13% margin).
Watch for
Q4 FY26 PAT was ~₹290 Cr. Q1 typically reflects seasonal softness and higher finance costs.
A strong Q1 would hold margins above 17%—confirming that Q4's operational leverage (higher utilization, pricing discipline) is structural, not transient. Revenue in the ₹1,700+ Cr range would suggest no seasonal cliff and export traction. A weak Q1 would show margin compression below 16%, signaling that Q4's margin beat was offset by lower volumes or raw-material headwinds. Revenue below ₹1,550 Cr would raise questions about export demand and volume sustainability heading into the capex cycle.
On Track with Guidance?
Management guided to margin improvement in FY27 vs FY26, with expectations for both standalone and consolidated performance to improve as the company progresses. Q4 FY26's 18% EBITDA margin is the proof point—a jump from Q3's 11% and well above the full-year 13% average. Q1 FY27 will be the first test: if margins hold in the 17–19% zone, it confirms the guidance is credible. Volumes matter too. The company is ramping specialty chemicals (higher-margin fluorination and fine-chemistry outputs) and has commenced capex on new downstream facilities. A flat-to-up Q1 revenue would signal that demand is holding despite macro softness in Europe.
What the Street Says
Since Last Quarter
Strategic capex and subsidiary moves dominate the filing scan. Deepak Chem Tech Limited (DCTL, the wholly-owned subsidiary driving new chemistry projects) has raised ₹120 Cr in 9% Optionally Convertible Redeemable Preference Shares, allocated to Deepak Phenolics—signaling debt-light funding for the HyCO plant (hydrogen-carbon monoxide synthesis, raw material for downstream fine chemicals). Deepak Nitrite itself has guaranteed a $78.43 M Term Loan for Deepak Oman Industries, a subsidiary, to fund operations and capex in Oman—a strategic bet on non-India diversification. Neither is a red flag; both are normal for specialty-chemical capex. Promoter holding flat at 49.33%, DII slightly up to 23.47%, FII stable at 6.19%—no insider selling or pledging. AGM scheduled for Aug 5, with director reappointments and dividend approval (FY26 dividend ₹7.50/share). Earnings call Aug 6 at 3:30 PM IST.
Key Watchpoints for Aug 4
1 · Can Q1 EBITDA margin hold 17–19%?
The most important line. Q4's 18% is the new watermark; if Q1 delivers above 16.5%, the Street's confidence in FY27 margin guidance strengthens. Below 15.5% and the capex thesis gets questioned.
2 · Revenue trajectory: ₹1,550–1,750 Cr or cliff?
Volume and pricing are the tells. In-range delivery confirms export demand and pricing power are intact; a miss raises questions about macro headwinds.
3 · Capex progress and phasing
Management will discuss the ₹1,500–2,000 Cr fine-chemicals and fluorination capex plan. How much is committed by Q1, and when are first earnings accretions expected? A clear schedule is key to credibility.
4 · FY27 full-year margin and revenue guidance
Will management quantify the margin band for FY27? Consensus is 17–20% sustainable, but specificity matters. Any revisit to the guidance would signal macro or market anxiety.
5 · Dividend sustainability & capital allocation
FY26 dividend was ₹7.50/share (375% payout). With capex ramping, watch for commentary on dividend sustainability and buyback plans. Retail investors will parse this.
In Summary
Deepak Nitrite is at an inflection: Q4 FY26 proved operational leverage in specialty chemicals (18% EBITDA margin vs 13% full-year average), and FY27 is when the capex cycle begins in earnest. The street prices in 21–36% upside on the bet that fine chemicals and fluorination products will sustain 17–20% margins as they scale. Q1 FY27 is not the capex payoff quarter—it's the margin hold-or-break quarter. Revenue in the ₹1,650 Cr zone with EBITDA margin above 17% would signal that the beat is real, not one-off. A miss on either front, and the narrative shifts to execution risk. Watch the earnings call carefully for capex phasing and FY27 guidance specificity; that's where the real debate is.